TY - JOUR
T1 - Better pandemic influenza preparedness through adjuvant technology transfer
T2 - Challenges and lessons learned
AU - Lemoine, Céline H.
AU - Nidom, Reviany V.
AU - Ventura, Roland
AU - Indrasari, Setyarina
AU - Normalina, Irine
AU - Santoso, Kuncoro Puguh
AU - Derouet, Francis
AU - Barnier-Quer, Christophe
AU - Borchard, Gerrit
AU - Collin, Nicolas
AU - Nidom, Chairul A.
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/5
Y1 - 2021/5
N2 - Adequate global vaccine coverage during an influenza pandemic is essential to mitigate morbidity, mortality, and economic impact. Vaccine development and production needs to be sufficient to meet a vast global demand, requiring international cooperation and local vaccine production capacity, especially in resource-constrained countries. The use of adjuvants is one approach to augment the number of available vaccine doses and to overcome potential vaccine shortages. Appropriately selected adjuvant technologies can decrease the amount of vaccine antigen required per dose, may broaden or lengthen the conferred protection against disease, and may even allow protective single-dose vaccination. Here we describe a technology transfer collaboration between Switzerland and Indonesia that led to the establishment of a vaccine formulation platform in Surabaya which involved the transfer of equipment and expertise to enable research and development of adjuvanted vaccine formulations and delivery systems. This new Indonesian capability aims to facilitate local and regional access to know-how relating to adjuvanted vaccine formulations, thus promoting their application to local vaccine developers. In this review, we aim to share the “lessons learned” from this project to both support and inspire future scientific collaborations of a similar nature.
AB - Adequate global vaccine coverage during an influenza pandemic is essential to mitigate morbidity, mortality, and economic impact. Vaccine development and production needs to be sufficient to meet a vast global demand, requiring international cooperation and local vaccine production capacity, especially in resource-constrained countries. The use of adjuvants is one approach to augment the number of available vaccine doses and to overcome potential vaccine shortages. Appropriately selected adjuvant technologies can decrease the amount of vaccine antigen required per dose, may broaden or lengthen the conferred protection against disease, and may even allow protective single-dose vaccination. Here we describe a technology transfer collaboration between Switzerland and Indonesia that led to the establishment of a vaccine formulation platform in Surabaya which involved the transfer of equipment and expertise to enable research and development of adjuvanted vaccine formulations and delivery systems. This new Indonesian capability aims to facilitate local and regional access to know-how relating to adjuvanted vaccine formulations, thus promoting their application to local vaccine developers. In this review, we aim to share the “lessons learned” from this project to both support and inspire future scientific collaborations of a similar nature.
KW - Adjuvanted vaccines
KW - Global health
KW - Influenza
KW - Lessons learned
KW - Pandemic preparedness
KW - Technology transfer
UR - http://www.scopus.com/inward/record.url?scp=85105935254&partnerID=8YFLogxK
U2 - 10.3390/vaccines9050461
DO - 10.3390/vaccines9050461
M3 - Review article
AN - SCOPUS:85105935254
SN - 2076-393X
VL - 9
JO - Vaccines
JF - Vaccines
IS - 5
M1 - 461
ER -